ArticleEJNMMI research2026
Simultaneous perfusion and dopaminergic imaging using dual-isotope CZT SPECT/CT in dementia with Lewy bodies.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent diagnostic criteria for dementia with Lewy bodies (DLB) include indicative and supportive biomarkers, some of which are typically assessed separately using dopamine transporter or perfusion imaging. Cadmium-zinc-telluride (CZT) Single Photon Emission Computed Tomography (SPECT) cameras improve simultaneous dual isotope acquisition using [99mTc]-hexamethylpropyleneamine oxime ([99mTc]TcHMPAO) (perfusion) and N-(3-Fluoropropyl)-2β-carbomethoxy-3β-(4-[123I]iodophenyl)nortropane ([123I]FP-CIT; dopamine transporter), allowing the assessment of one indicative and two supportive biomarkers in a single session. This study aimed to describe the results of dual-isotope brain SPECT imaging in a cohort of patients clinically diagnosed with DLB and to compare clinical characteristics, cognition, structural atrophy, and Alzheimer’s disease (AD) biomarkers, between imaging outcomes.
resultsThis retrospective single-center study included a total of 56 consecutive patients (mean ± standard deviation age 80.4 ± 7.8 years; 34% females) referred from an expert memory center finally diagnosed as DLB and who underwent a dual-isotope brain SPECT. Based on core clinical features from Mc Keith et al. revised diagnostic criteria, 40 patients (71%) were classified as probable DLB and 16 (29%) as possible DLB. Reduced dopamine transporter uptake (indicative biomarker) was observed in 84% of patients, while cerebral hypoperfusion was found in 100%. Supportive biomarkers such as cingulate island sign and occipital hypoperfusion were present in 29% and 55%, respectively. All 9 patients with normal dopamine transporter imaging had cerebral hypoperfusion and 3 of them presented supportive biomarkers of DLB. No significant association was found between imaging biomarker results and global cognition score, each core clinical features individually, medial temporal lobe atrophy, or CSF biomarkers for AD.
conclusionDual-isotope brain SPECT using CZT frequently identifies dopamine transporter abnormalities in patients with DLB, always in conjunction with perfusion abnormalities. Patients with normal dopamine transporter imaging always present perfusion abnormalities. This imaging approach provides a more comprehensive assessment of indicative and supportive biomarkers in DLB, without increasing scan duration, potentially enhancing diagnostic confidence in clinical practice, particularly in challenging cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.